author-photo

W. K. Alfred Yung

University of Texas MD Anderson Cancer Center

346

Papers

33090

Citations

Citation Trend

Filter By

Papers (346) Sort By

Journal Conference Others

EXTH-06. ATR INHIBITORS AS MONOTHERAPY AND COMBINATORIAL THERAPY WITH TEMOZOLOMIDE IN PRECLINICAL GLIOBLASTOMA MODELS

2021 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
EPCO-06. AGE- AND REGION-SPECIFIC MULTI-OMIC CHARACTERIZATION OF H3-K27M MUTANT DIFFUSE MIDLINE GLIOMA

2021 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
Results of a phase I trial to assess the safety of macitentan in combination with temozolomide for the treatment of recurrent glioblastoma

2021
Show All
- Source
- Cite
- Save
Citations (0)
The Promise of DNA Damage Response Inhibitors for the Treatment of Glioblastoma

2021
Show All
- Source
- Cite
- Save
Citations (2)
Integrated analysis of telomerase enzymatic activity unravels an association with cancer stemness and proliferation.

2021 Nature Communications
Show All
- Source
- Cite
- Save
Citations (8)
CTIM-04. BIOMARKER IMMUNE CORRELATES IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) TREATED WITH ATEZOLIZUMAB IN COMBINATION WITH TEMOZOLOMIDE (TMZ) AND RADIATION

2021 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)
PARP mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma.

2021 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (3)
Report of National Brain Tumor Society Roundtable Workshop on Innovating Brain Tumor Clinical Trials: Building on Lessons Learned from COVID-19 Experience.

2021 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (1)
Abstract CT238: Phase 2 study of dianhydrogalactitol (VAL-083) inpatients with MGMT-unmethylated, bevacizumab-naivepatients with MGMT-unmethylated, bevacizumab-naïve glioblastoma in the recurrent and adjuvant setting

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
PATH-05. A RETROSPECTIVE STUDY OF TREATMENT STRATEGIES AND OUTCOMES IN WHO GRADE II AND III ISOCITRATE DEHYDROGENASE (IDH) WILD-TYPE ASTROCYTOMA

2020 Neuro-oncology
Show All
- Source
- Cite
- Save
Citations (0)